Merck

Merck advanced 2.36% today, hitting an intraday peak of $131.04 with a closing price of $130.48, trading near its 52-week high of $131.74, bringing year-to-date gains to 22.57%. The rally was fueled by significant pipeline advances: the once-weekly oral HIV regimen developed with Gilead maintained virological suppression in Phase 3 trials, positioning it as a blockbuster-potential therapy set to transform HIV treatment. Additionally, FDA approval of Merck's oral PCSK9 cholesterol inhibitor marks the first-in-class achievement, adding a meaningful new growth pillar. Institutional support strengthened as BlackRock increased its voting rights to 8.17%, reflecting confidence in long-term prospects. However, Q1 results showed net losses (EPS -$1.72, net income -$4.24 billion) despite revenue growth of $16.29 billion (+4.87% year-over-year), signaling near-term profitability challenges. With a PE ratio of 36.07, the stock's further performance hinges on successful commercialization of these pipeline assets.

Merck edged up 0.96% to $127.47, approaching 52-week highs just 3.24% below its peak of $131.74, with year-to-date gains of 19.75%. Recent positive catalysts include FDA approval of an oral PCSK9 cholesterol drug (the first of its kind), Phase 3 success for an investigational once-weekly HIV regimen developed with Gilead that sustained viral suppression, and exploration of acquiring genomics firm Personalis. Q1 2026 results, however, revealed a net loss of $4.24 billion and negative EPS of -$1.72 (a 185.57% YoY decline), though operating revenue remained resilient at $16.286 billion (+4.87% YoY), pressuring profitability near-term. Current valuation is elevated (PE 35.24, PB 6.86), and the Trump administration set August 1 as the start date for generic drug tariffs potentially reaching 200%, which could create additional headwinds for the pharmaceutical sector.

Merck rose 1.5% to $126.26 today, supported by recent product-pipeline catalysts. Last week the company secured FDA approval for Verquvo, the first-in-class oral PCSK9 cholesterol agent approved for once-daily administration—a potential blockbuster entering a large market with significant unmet need. Concurrently, Merck and Gilead announced their investigational once-weekly oral HIV combination regimen maintained robust virological suppression in late-stage clinical trials. Q1 revenue reached $16.29 billion, up 4.87% year-over-year, though the quarter swung to a net loss of $4.24 billion (EPS -$1.72), largely due to significant one-time charges. Year-to-date the stock has advanced 18.61% and now trades near its 52-week peak of $131.74 set just days ago (currently 4.16% below), well above both the 20-day and 60-day moving averages. The sharp deterioration in Q1 profitability warrants monitoring as the company's ability to effectively commercialize these new therapies will be critical to delivering value.

Merck (MRK) declined to $124.40 from the prior close of $127.50 during today's regular trading session, a retreat of roughly 2.4%, primarily driven by profit-taking following the recent FDA approval of LIPFENDRA (enlicitide), the first and only once-daily oral PCSK9 inhibitor—the stock had surged to a 52-week high of $131.74 on July 17 in the wake of this positive catalyst. However, weakened Q1 2026 earnings results tempered upside momentum considerably: despite operational revenue of $16.29 billion climbing 4.87% year-over-year, net profit swung to a significant loss of $4.24 billion (compared to a $2.96 billion profit in Q4, representing a 183.48% year-over-year deterioration), while EPS collapsed to -$1.72. At a current P/E ratio of 34.39, valuation remains at elevated levels, which may exacerbate near-term selling pressure when combined with disappointing bottom-line results. On the positive side, additional Keytruda FDA approvals and reported takeover interest in Personalis continue to provide catalysts for future upside, and the stock remains up 16.86% year-to-date, trading just 0.6% below its 20-day moving average of $125.04, suggesting the broader uptrend remains intact despite today's pullback.

Merck surged intraday to a new 52-week high of $131.66 before closing at $127.50, driven by FDA approval of LIPFENDRA (enlicitide)—the first and only once-daily oral PCSK9 inhibitor for cholesterol management—alongside positive Keytruda data showing success in late-stage uterine cancer trials and favorable lung cancer results from the Kelun-Biotech partnership. Year-to-date, the stock has climbed 19.77% and currently trades well above its 60-day moving average of $118.24. The intraday retreat to near-flat reflects profit-taking pressure after reaching fresh 52-week highs. On the earnings front, Q1 results inject complexity: EPS dropped to -$1.72 with net income swinging to a loss of -$4.24 billion, even as revenue demonstrated resilience with 4.87% YoY growth to $16.29 billion. This sharp profitability contraction amid topline growth raises questions about one-time charges or operational headwinds, tempering enthusiasm despite strong pipeline progress.